ADVISORY/FDA Approves PEG-INTRON for Treatment of Chronic Hepatitis C.Health/Medical Editors ADVISORY...for Monday (Jan. 22) NOTE TO EDITORS: Multimedia Assets Available With This Story Include Corporate Logo, Video --(BUSINESS WIRE) Schering-Plough Corporation (NYSE NYSE See: New York Stock Exchange :SGP SGP Singapore (ISO Country code) SGP Schering-Plough (stock symbol) SGP Stability and Growth Pact SGP Southern Great Plains SGP Staatkundig Gereformeerde Partij SGP Speedway Grand Prix ) announces that the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. has approved PEG-INTRON(tm) (peginterferon alfa-2b peginterferon alfa-2b PEG-Intron, PegIntron (UK), ViraferonPeg (UK) Pharmacologic class: Immunomodulator Therapeutic class: Immunologic agent Pregnancy risk category C (monotherapy), X ) Powder for Injection as once-weekly monotherapy for the treatment of chronic hepatitis Chronic hepatitis Long lasting inflammation of the liver due to viruses or other causes. Mentioned in: Tube Compression of the Esophagus and Stomach chronic hepatitis C in patients not previously treated with alpha interferon who have compensated liver disease and are at least 18 years of age. PEG-INTRON is the first and only pegylated interferon approved for marketing in the United States. You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?1792 This multimedia news story is for free and unrestricted use on your news or information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics, and photos. If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion